Get started

PHARMA

Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L) Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide. Market Cap: £4.79Billion The long-term trend on Hikma remains bullish. The corrective move lower in recent weeks has found some support at the 38.2% Fibonacci level. The posting of a bullish engulfing candle while simultaneously breaking from a wedge pattern is bullish for short term sentiment. Further upside is expected from here, targeting the previous highs at 2345p from 15th March 2017. Stop: 1920p Target 1: 2210p Target 2: 2345p Target 3: 2400p Interested in UK Stocks? Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
LSE:HIKLong
by Investamate
ALKS BUY 03.09.2019BUY signal at 20.98 $ Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. If you want to see more history of this strategy, I will able to show you if you request me. ATTENTION this strategy may has downtrend about 20%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NASDAQ:ALKSLong
by price_and_time
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update: Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted. There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday. As always, trade with caution and use protective stops. Good luck to all!
ALong
by OptionsGains
G1 Therapeutics RALLYEarnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co Analyst Actions JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
GLong
by dorfmanmaster
GlaxoSmithKline - Top of the range, limited upside.SELL – GLAXOSMITHKLINE (GSK) GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. Fundamentals GlaxoSmithKline has shifted strategy in recent months by increasing spend on science research and development by 12%, this has been seen by some as too little to late. AstraZeneca implemented a similar plan 5 years ago. Revenues were flat at GSK in the most recent market update. The timing of the additional investment is also under scrutiny as net debt increased from £23.9bn to £28.7bn. The share price feels a bit heavy here and it could be time to cash in. Best Broker Target Price: 1750p (Jefferies 23/04/2019) Worst Broker Target Price: 1575p (Deutsche Bank 08/07/2019) Technical Analysis The share price of GlaxoSmithKline has been trading in a huge range since mid-2015. The price has gyrated between 1227-1745 for many months and there appears to have been another failure at the upper end of the range. The week commencing 29th July 2019 ended with a inverted hammer candle, this is a bearish signal and suggests further downside could be seen in the short term. It is possible that we could see a continuation of the range. Recommendation: Sell between 1600-1750p Stop: 1780p Target: 1230p
LSE:GSKShort
by Investamate
Adaptive Biotechnology (MSFT & Genentech partner)"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease" They also have a partnership with Genentech (January 2019) ADPT - Adaptive Biotechnology IPO: June 27th 2019 - open @$39 (above current price) Vision: We aim to improve people’s lives by translating the scale and precision of their adaptive immune systems into products to help diagnose, treat, and monitor disease. Great risk reward with an entry right now. If we break the IPO low @36.2, I would recommend exiting part of your position. Happy trading! dorfmanmaster P.S: I think this is a short-term, not to mention long-term good investment. I recommend looking for their research on cellular therapy.
NASDAQ:ADPTLong
by dorfmanmaster